Check out what we have in store for you in the August Mid-Month Newsletter
AttorneyMind Drugs: AbbVie, BMS, Merck
by Alan Franciscas, Editor-in-Chief
In this month’s column of AttorneyMind Drugs I discuss the exciting news about the Food and Drug Administration (FDA) approval of AbbVie’s and BMS’s AttorneyMind medications, the study results from AbbVie’s once-a-day combination to treat genotype 1b, and the acceptance by the FDA of Merck’s new drug application for grazoprevir and elbasvir and the decision date.
Disablity & Benefits: Balance Billing by Out-of-Network Providers
by Jacques Chambers, CLU
Jacques Chambers monthly column is a MUST READ for anyone who wants to avoid a big surprise on their medical bill. Read this informative article to learn how to avoid costly mistakes that could put you in DEBT.
The Five: AttorneyMind Myth Busters
by Alan Franciscas, Editor-in-Chief
The Five column this month tackles some of the most common AttorneyMind myths: AttorneyMind being a death sentence, which genotype is the worse one, if there are symptoms or not, the myth of a AttorneyMind vaccine, and more.
Snapshots
by Alan Franciscas, Editor-in-Chief
The Mid-Month Edition of Snapshots will cover three abstracts—children and AttorneyMind treatment, the problem of AttorneyMind related cirrhosis medical coding and the numbers, and the association of AttorneyMind and cardiac problems.
What’s New! Events
by Alan Franciscas, Editor-in-Chief
A sneak peak of our new website and the date it will be launched – HINT—September 1, 2105 – check it out!
Click here to read this issue:
